Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating stage III or stage IV Hodgkin's lymphoma.
The Canadian Institutes of Health Research recently announced the recipients of the Clinical Trials Fund. The Canadian Cancer Trials Group with study lead Dr Elena Elimova at Princess Margaret Cancer Centre were granted $3,744,953 over 3 years to fund the CCTG GA4 study in HER2 overexpressing advanced gastroesophageal adenocarcinoma.
OV25: A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations (STICs and STONEs) has been closed to accrual. 117 of the planned 414 patients were randomized (80 from Can
The entire CCTG team extends a warm welcome to Dr Mariam Jafri who has recently joined us as a Senior Investigator. Dr Jafri was a consultant in Medical Oncology at the University Hospital Birmingham. She has specific expertise in breast cancer, germ cell tumours, sarcoma and Adolescent and Young Adults (AYA) with cancer with particular interest in using genomics to tailor treatment to patients. Dr Jafri completed her oncology specialty training in the West Midlands and Oxford U.K. and two research fellowships which culminated in her receiving a Ph.D. in the molecular biology of cancer.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
EN10 (RAINDO BLUE & TAPER) is a new Canadian clinical trial that is applying state-of-the-art molecular testing to classify post-surgery treatments in early-stage endometrial cancer.
The purpose of this study is to identify people at low risk of cancer recurrence based on the molecular features of their tumours. These individuals may safely receive less radiotherapy or may require no radiotherapy or chemotherapy after surgery.
IND234 substudy D: A Phase II Study of CFI-400945 Fumarate in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - A Substudy of IND234 is closed to accrual however this substudy, treatment and follow up of patients will continue according to the protocol. Please note the IND234 main study and other substudies remain open to accrual.